Heron Therapeutics CEO Barry Quart's 2021 pay rises 2% to $5.4M
Heron Therapeutics reports 2021 executive compensation
By ExecPay News
Published: April 25, 2022
Heron Therapeutics reported fiscal year 2021 executive compensation information on April 25, 2022.
In 2021, five executives at Heron Therapeutics received on average a compensation package of $2.4M, a 8% decrease compared to previous year.
Average pay of disclosed executives at Heron Therapeutics
Barry D. Quart, Chief Executive Officer, received $5.4M in total, which increased by 2% compared to 2020. 42% of Quart's compensation, or $2.3M, was in option awards. Quart also received $392K in non-equity incentive plan, $700K in salary, $2.1M in stock awards, as well as $8.7K in other compensation.
For fiscal year 2021, the median employee pay was $268,692 at Heron Therapeutics. Therefore, the ratio of Barry D. Quart's pay to the median employee pay was 20 to one.
Kimberly Manhard, Executive Vice President, Drug Development, received a compensation package of $1.9M, which decreased by 15% compared to previous year. 31% of the compensation package, or $584K, was in stock awards.
John Poyhonen, President and Chief Commercial Officer, earned $1.8M in 2021, a 31% decrease compared to previous year.
David Szekeres, Chief Operating Officer, received $1.8M in 2021, which decreases by 26% compared to 2020.
Lisa Peraza, Chief Accounting Officer, earned $797K in 2021, a 50% decrease compared to previous year.
Related executives
Barry Quart
Heron Therapeutics
Chief Executive Officer
John Poyhonen
Heron Therapeutics
President and Chief Commercial Officer
Kimberly Manhard
Heron Therapeutics
Executive Vice President, Drug Development
David Szekeres
Heron Therapeutics
Executive Vice President, Chief Commercial Officer
Lisa Peraza
Heron Therapeutics
Chief Accounting Officer
You may also like
Source: SEC filing on April 25, 2022.